argenx SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Karen Massey
- Full Time Employees
- 1,863
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Laarderhoogtweg 25 Amsterdam NH Netherlands 1101 EB
- IPO Date
- May 18, 2017
- CIK
- 0001697862
- Website
- argenx.com
- Similar Companies
- Business
- argenx SE, a commercial-stage global immunology company, develops and commercializes differentiated antibody-based therapies targeting severe autoimmune diseases using its proprietary Immunology Innovation Program and SIMPLE Antibody platform; its lead product VYVGART (efgartigimod) is an FcRn blocker approved for generalized myasthenia gravis in the United States, Europe, Japan, Israel, Canada and Mainland China, as well as for chronic inflammatory demyelinating polyneuropathy, with subcutaneous formulations including pre-filled syringes launched to enhance patient access and ongoing label expansions into broader myasthenia gravis populations such as seronegative, pediatric and ocular via studies like ADAPT-SERON, ADAPT-JR and ADAPT-OCULUS; the pipeline features advancing candidates like ARGX-213 targeting FcRn, ARGX-121 for IgA, ARGX-109 for IL-6 and ARGX-220 as a novel sweeping antibody, alongside earlier programs and out-licensed assets including LP0145 (ARGX-112) to LEO Pharma for atopic dermatitis, AGMB-101 (ARGX-114) to AgomAb Therapeutics for fibrotic diseases and ARGX-115 (ABBV-151) to AbbVie for oncology. argenx SE operates in key markets including the United States, Europe, Japan and Greater China through partnerships such as with Zai Lab; it was founded in 2008 in Ghent, Belgium by Tim van Hauwermeiren, Hans de Haard and Torsten Dreier, with headquarters in Amsterdam, Netherlands, and maintains subsidiaries like argenx BV in the Netherlands, argenx SAS in France and argenx UK Ltd. Recent developments include expansion of VYVGART into immune thrombocytopenia and multifocal motor neuropathy via registrational programs like ADVANCE and EMPASSION with topline data anticipated, autoinjector development for 2027 launch, four new pipeline nominations through the Immunology Innovation Program in 2025, sustained R&D investment supported by approximately EUR 2.6 billion in cash equivalents as of late 2024, and global commercial infrastructure growth alongside strategic collaborations leveraging technologies like Halozyme's subcutaneous delivery.
Company News
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
argenx to Present at Upcoming Investor Conferences
argenx Completes Acquisition of Forte Biosciences, Inc.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis Transcript
These Analysts Boost Their Forecasts On Argenx
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Argenx says efgartigimod met main goal in myositis trial
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
What Makes Argenx (ARGX) a New Buy Stock
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
FTRE vs. ARGX: Which Stock Is the Better Value Option?